NeoGenomics, Inc. (NasdaqCM:NEO) agreed to acquire Trapelo Health for $65 million on March 24, 2021. The consideration consists of $35 million in cash on hand and $30 million in NeoGenomics common stock is subject to satisfaction of certain customary closing conditions. Trapelo employees will join NeoGenomics. The transaction is expected to close in April 2021.